Abakavir-AVS

Abakavir-AVS – antiviral means, active concerning HIV.

Form of release and structure

Dosage form – tablets, film coated: a round biconvex form, brownish-yellow color, at a break two layers from which a tablet kernel – from color, white to white with a yellow shade are visible (10 pieces in a blister strip packaging, in a cardboard pack of 6 packagings; on 60 pieces in polymeric banks or bottles, in a cardboard pack of 1 bank or a bottle).

Abakavira-AVS active ingredient – an abakavira sulfate, in 1 tablet – 0,351 g that is equivalent to 0,3 g of an abakavir.

Auxiliary components: silicon dioxide colloid (aerosil), cellulose microcrystallic, magnesium stearate, sodium carboxymethylstarch.

Structure of a film cover: опадрай II 85F220031 yellow (titanium dioxide, polyvinyl alcohol, talc, macrogoal 4000, dye ferrous oxide yellow).

Indications to use

Use of Abakavira-AVS is shown as a part of a combination therapy of HIV infection.

Contraindications

• Moderate and heavy abnormal liver functions;
• The children's age up to 3 months and weight is less than 14 kg;
• Breastfeeding period;
• Hypersensitivity to an abakavir and auxiliary components of drug.

With care should apply the patients inclined to developing of coronary heart disease, and also at arterial hypertension, a diabetes mellitus, a dislipidemiya, smoking.

Expediency of purpose of drug during pregnancy is defined by the doctor, having weighed the expected effect of therapy for mother and potential threat for a fruit.

Route of administration and dosage

Pill is taken inside.

The recommended dosing:

• Adults: on 0,3 g 2 times a day;
• Children from 3 months to 16 years: from calculation for 0,008 g on 1 kg of weight 2 times a day.

Side effects

• Alimentary system: appetite loss, abdominal pain, nausea, ulceration of a mucous membrane of a mouth, vomiting, diarrhea, liver failure, increase in activity of enzymes of a liver;
• Musculoskeletal system: often – a giperlaktatemiya; seldom – lactoacidosis, accumulation or redistribution of fatty tissue (the probability of emergence depends on anti-retrovirus drugs of the accompanying therapy and many other factors);
• Nervous system: drowsiness, headache, paresthesias;
• Urinary system: a renal failure, increase in level of concentration of creatinine in blood serum;
• Respiratory system: pharyngalgia, cough, short wind, respiratory insufficiency, respiratory distress syndrome of adults;
• Lymphatic system and system of a hemopoiesis: lymphopenia;
• Musculoskeletal system: mialgiya; seldom – arthralgias, рабдомиолиз, increase in activity of a kreatinfosfokinaza;
• Dermatological reactions: skin rash (is more often urtikarny, makulopapulezny); very seldom – a mnogoformny exudative erythema (including a toxic epidermal necrolysis, Stephens-Johnson's syndrome);
• Others: feeling of fatigue, hypostases, fever, indisposition, lymphadenopathy, conjunctivitis, arterial hypotension, anaphylactic reactions.

Special instructions

Against the background of use of an abakavir, is more often during the first 6 weeks of treatment, emergence of symptoms of hypersensitivity is possible, in this case drug should be cancelled.

There is a risk of development of fatty dystrophy of a liver, a hepatomegalia, lactoacidosis, including with fatal effects (more often women are subject to the specified complications).

Treat symptoms of lactoacidosis: a loss of appetite, the general weakness, bystry loss of weight of not clear etiology, disturbance from respiratory system (an asthma, a tachypnea) and digestive tract.

In case of clinical signs or disturbance of the laboratory indicators confirming lactoacidosis or a hepatotoxic (at a hepatomegalia and fatty dystrophy of a liver even without the expressed increase in activity of aminotransferases), reception of tablets needs to be stopped.

Use of Abakavira-AVS should be accompanied with regular clinical inspection of patients regarding redistribution of a hypodermic fatty tissue as the anti-retrovirus combination therapy can cause development of a syndrome of a lipodystrophy. At disturbance of lipidic exchange (level of concentration of lipids and glucose in blood serum) to the patient appoint additional treatment.

In the presence of asymptomatic opportunistic infections (or oligosymptomatic) with the expressed immunodeficiency at the time of the beginning of the combined anti-retrovirus therapy treatment can cause strengthening of symptoms of an infection in HIV-positive patients and lead to serious consequences. Characteristic pathologies are the Cytomegaloviral retinitis, a focal or generalized mikobakterialny infection, the pneumonia caused by Pneumocystis jirovecii.

Because of big risk of development of complications of HIV infection or opportunistic infections during reception of Abakavira-AVS patients need constant observation of the doctor for timely purpose of adequate therapy.

Medicinal interaction

The possibility of simultaneous use of other medicines during treatment abakaviry is defined by the attending physician.

Terms and storage conditions

To store in the place, unavailable to children, at a temperature not above 25 °C.

Period of validity – 2 years.